CatalYm‘s visugromab at SITC 2025
CatalYm's GDF-15 neutralizing antibody visugromab featured at SITC 2025
November 07, 2025 – Published at 9.00 am ET / 3.00 pm CET – We are excited to share that our Phase 1/2 GDFATHER-01 trial evaluating our lead candidate Visugromab in various solid tumor indications will be highlighted across multiple presentations at the upcoming SITC Annual Meeting 2025.
Dr. Ignacio Melero, principal investigator of the trial, will deliver an oral presentation and a poster presentation showcasing our latest long term follow-up data in nsqNSCLC, UC and HCC patients, demonstrating remarkable durability of response in a heavily pre-treated, late-stage patient population.
Interested in learning more? Connect with our CSO, Dr. Stefan Ries, who will be on the ground in National Harbor, MD, and is looking forward to discussing our data to date and why GDF-15 is an attractive emerging target in #ImmunoOncology and #Cachexia.
We would also like to extend a heartfelt congratulations to Dr. Melero for being honored as the 2025 SITC Fellow of the Academy of Immuno-Oncology for his outstanding work in bringing novel immunotherapies to cancer patients.